NutriBand’s quarterly Revenue fell to $437,514 from $622,452, while its net loss narrowed to $880,561 from $23,814,166 available to common shareholders. The results matter because a principal customer shifted operations to Asia, further Demand weakness is expected, and cash declined to $3,421,615 during the period.

Key Highlights

  • Gross profit increased to $182,874 from $156,881 as revenue costs fell to $255,640.
  • Cash and cash equivalents stood at $3,421,615, while total current liabilities were $907,048.
  • NutriBand recorded zero revenue from 4P Therapeutics during the quarter as its main contract wound down.

NutriBand Inc. (NASDAQ: NTRB) generated $437,514 in revenue for the three months ended July 31, 2026, down from $622,452 in the comparable period. The company recorded a net loss of $880,561, or $0.07 per basic and diluted share, compared with a loss of $23,814,166 available to common shareholders, or $2.12 per share, previously. Revenue was affected by a principal customer moving operations to Asia, while further demand weakness is expected during the balance of the current year.

Gross Profit Reaches $182,874

Cost of revenues fell to $255,640 from $465,571, producing Gross Profit of $182,874 compared with $156,881. The company attributed the stronger gross Margin to a more favourable sales mix. Research and Development spending on the Aversa Fentanyl product was $322,194, compared with $562,554, reflecting lower labour costs. Interest expense was $4,874, while interest income reached $14,950. The comparable figures were $5,773 and $8,649, respectively.

Customer Shift Reduces Revenue

Revenue during the quarter came from Pocono Pharmaceuticals, while 4P Therapeutics recorded zero revenue. The filing attributed the decline in Pocono Pharmaceuticals revenue to a principal customer transferring operations to Asia. The company also said demand is expected to decrease during the remainder of the current year.

Cash Balance Stands at $3,421,615

Cash and cash equivalents were $3,421,615 at July 31, 2026, compared with $4,574,857 at January 31, 2026. Total current Assets were $3,819,383, including Accounts Receivable of $23,592, inventory of $170,733 and prepaid expenses of $203,443. Total assets stood at $6,293,097. Goodwill was $1,719,535, property and equipment were $530,085, and intangible assets were $170,094. Current liabilities totalled $907,048. Accounts Payable and accrued expenses were $644,518, deferred revenue was $100,121, the current portion of operating Lease liabilities was $33,967, and current notes payable were $128,442. Total liabilities were $964,358, including a note payable of $25,099 net of the current portion and operating lease liabilities of $32,211 net of the current portion.

Six-Month Cash Use Continues

For the six months ended July 31, 2026, revenue was $870,913, compared with $1,289,884 in the comparable period. Operating Activities used $1,148,103 in cash during the six-month period. The principal adjustments to net loss included Depreciation and Amortisation of $67,503 and $772,828 from warrants and Options issued for services. NutriBand had 12,155,683 shares of common stock outstanding as of September 4, 2026.